Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs

Journal of Child Neurology
William G OndoAnthony Davis

Abstract

Weight gain occurs with most neuroleptic drugs used to treat tics. Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor, inhibits dopamine release. It is used to treat a variety of hyperkinetic movement disorders, including tics. Weight gain over time was compared in a group of pediatric tic patients taking only tetrabenazine with an age-matched group of tic patients taking only neuroleptic drugs. Age in the tetrabenazine group (n = 36, 32 males) at initial therapy was 13.4 (SD 3.3) years. They were monitored for 25.2 (SD 12.3) months. The average dose of tetrabenazine (all visits) was 54.4 (SD 26.6) mg/d. In the neuroleptic group (n = 41, 33 males), the age at therapy onset was 12.3 +/- 4.0 years. They were monitored for 18.9 (SD 14.8) months. Weight increase was 0.8 lb/mo in the tetrabenazine group compared with 1.7 lb/mo in the neuroleptic group (P = .006). Most patients who switched from a neuroleptic drug to tetrabenazine subsequently lost weight. Although the study was not designed to compare efficacy, this tended to be greater with tetrabenazine than with neuroleptic drugs.

References

Oct 20, 2001·The New England Journal of Medicine·J Jankovic
Apr 12, 2003·Neurology·L ScahillB S Peterson
Dec 17, 2004·Clinical Neuropharmacology·D PaleacuS Badarny
Feb 10, 2006·Expert Review of Neurotherapeutics·Christopher Kenney, Joseph Jankovic
Nov 30, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Christopher KenneyJoseph Jankovic

❮ Previous
Next ❯

Citations

Mar 30, 2011·European Child & Adolescent Psychiatry·Veit RoessnerUNKNOWN ESSTS Guidelines Group
Sep 16, 2010·Current Treatment Options in Neurology·Gholson J LyonRoger Kurlan
May 30, 2014·Current Neurology and Neuroscience Reports·Irene A Malaty, Umer Akbar
Oct 22, 2011·Expert Review of Neurotherapeutics·Joseph Jankovic, Kathleen Clarence-Smith
Mar 5, 2016·Current Neurology and Neuroscience Reports·Aysegul Gunduz, Michael S Okun
Mar 22, 2016·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Martha M Rumore
Aug 12, 2009·Pediatric Neurology·Roosje S DegrauwDonald L Gilbert
Jun 27, 2009·Neurologic Clinics·Joohi Jimenez-Shahed
Dec 17, 2008·Pharmacoepidemiology and Drug Safety
Apr 13, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph Jankovic, Roger Kurlan
Nov 8, 2016·Expert Opinion on Pharmacotherapy·Joseph Jankovic
Aug 26, 2009·The Journal of School Nursing : the Official Publication of the National Association of School Nurses·Tracy Golder
Feb 23, 2011·Therapeutic Advances in Neurological Disorders·Clare M EddyAndrea E Cavanna
Nov 9, 2011·Nature Reviews. Neurology·Kevin St P McNaught, Jonathan W Mink
Dec 27, 2011·Journal of Clinical Psychopharmacology·Gary RemingtonNaima Javaid
Aug 29, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Andrew Billnitzer, Joseph Jankovic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

© 2021 Meta ULC. All rights reserved